Aripiprazole
- PDF / 169,486 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 34 Downloads / 152 Views
1 S
Rhabdomyolysis: case report A 45-year-old man developed rhabdomyolysis during treatment with aripiprazole for a substance-induced psychotic disorder. This case was reported to the Spanish Pharmacovigilance Service. The man presented in Spain with generalised myalgias and choluria for 24 hours following a mild sporadic physical activity. He had a complex medical history including parenteral drug abuse, bipolar disorder and substance-induced psychotic disorder. Three months prior to the presentation, he started receiving aripiprazole [route and dosage not stated], along with methadone and lorazepam. He denied any drug abuse in the previous month. His physical examination showed the presence of choluric urine. Laboratory tests revealed creatine kinase (CK) of more than 80 000 U/L and lactate dehydrogenase (LDH) of 2579 U/L. Urinalysis showed the presence of opiates, cannabis, heroin and methadone. The man was started on fluid therapy and urine alkalinisation with bicarbonate. However, CK levels were persistently high. Aripiprazole was then relaced with clonazepam. CK levels improved and normalised after two weeks. Based on these findings, he was diagnosed with aripiprazole related rhabdomyolysis. Rodriguez Fernandez L, et al. Rhabdomyolysis and antipsychotics. Medicina Clinica 153: 179-180, No. 4, 16 Aug 2019. Available from: URL: http://doi.org/10.1016/ 803506636 j.medcli.2018.10.035 [Spanish; summarised from a translation]
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
